Search research articles
Contact Us
Filters
Showing results (371-380 of 381) with videos related to
Page
of 39
Sort By:
European Urology Open Science
|
April 13, 2026
Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors
Philipp Mandel, Mike Wenzel, Felix Chun, et al.
Scientific Reports
|
June 17, 2026
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis
Brigida Anna Maiorano, Giandomenico Roviello, Alessandro Rizzo, et al.
European Urology Focus
|
July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
European Urology Oncology
|
November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study
Matteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Clinical Genitourinary Cancer
|
April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology
|
June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
European Urology Oncology
|
July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Minerva Urology and Nephrology
|
August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
Cancer Immunology, Immunotherapy : CII
|
September 7, 2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, et al.
Page
of 39
Search research articles
Search
Showing results (371-380 of 381) with videos related to
Sort By:
Page
of 39
European Urology Open Science
|
April 13, 2026
Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors
Philipp Mandel, Mike Wenzel, Felix Chun, et al.
Scientific Reports
|
June 17, 2026
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis
Brigida Anna Maiorano, Giandomenico Roviello, Alessandro Rizzo, et al.
European Urology Focus
|
July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
European Urology Oncology
|
November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study
Matteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Clinical Genitourinary Cancer
|
April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology
|
June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
European Urology Oncology
|
July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Minerva Urology and Nephrology
|
August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
Cancer Immunology, Immunotherapy : CII
|
September 7, 2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, et al.
Page
of 39